There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $110.00. The company’s shares closed last Thursday at $76.97, close to its 52-week low of $76.02.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $109.82, which is a 37.0% upside from current levels. In a report issued on May 13, Evercore ISI also initiated coverage with a Buy rating on the stock with a $113.00 price target.
See the top stocks recommended by analysts >>
Ionis Pharmaceuticals (IONS)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $82.00. The company’s shares closed last Thursday at $37.62, close to its 52-week low of $34.99.
According to TipRanks.com, Zhu is a 4-star analyst with an average return of
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $58.25, which is a 49.4% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $70.00 price target.
Ultragenyx Pharmaceutical (RARE)
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. The company’s shares closed last Thursday at $42.61.
According to TipRanks.com, Fauth ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $92.57 average price target, a 124.0% upside from current levels. In a report issued on May 2, RBC Capital also maintained a Buy rating on the stock with a $77.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
